SK Biopharmaceuticals Co., Ltd. (KRX:326030)
South Korea · Delayed Price · Currency is KRW 110,100
+900 (0.82%)
Feb 19, 2026, 9:10 AM KST
SK Biopharmaceuticals Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 675,406 | 547,596 | 354,892 | 246,179 | 418,645 | 25,999 |
Other Revenue | -0 | - | -0 | -0 | - | - |
| 675,406 | 547,596 | 354,892 | 246,179 | 418,645 | 25,999 | |
Revenue Growth (YoY) | 32.09% | 54.30% | 44.16% | -41.20% | 1510.23% | -79.01% |
Cost of Revenue | 33,828 | 43,101 | 34,082 | 37,768 | 22,336 | 1,974 |
Gross Profit | 641,578 | 504,495 | 320,809 | 208,411 | 396,309 | 24,025 |
Selling, General & Admin | 258,824 | 228,744 | 204,313 | 201,258 | 172,875 | 142,443 |
Research & Development | 165,779 | 161,270 | 137,126 | 122,817 | 114,526 | 108,441 |
Amortization of Goodwill & Intangibles | 4,763 | 6,017 | 5,758 | 5,055 | 4,251 | 2,559 |
Other Operating Expenses | 5,955 | 5,380 | 4,458 | 3,855 | 3,692 | 3,134 |
Operating Expenses | 443,263 | 408,156 | 358,331 | 339,489 | 301,350 | 263,524 |
Operating Income | 198,315 | 96,340 | -37,522 | -131,078 | 94,958 | -239,499 |
Interest Expense | -9,017 | -10,683 | -8,280 | -3,717 | -946.98 | -4,462 |
Interest & Investment Income | 7,652 | 10,146 | 9,317 | 6,755 | 2,343 | 2,121 |
Earnings From Equity Investments | -40,241 | -31,253 | -11,535 | -14,927 | -83,813 | - |
Currency Exchange Gain (Loss) | 500.42 | 16,706 | 1,026 | 8,878 | 11,985 | 494.22 |
Other Non Operating Income (Expenses) | -9,332 | -7,435 | -2,281 | -5,338 | -4,724 | -550.24 |
EBT Excluding Unusual Items | 147,877 | 73,820 | -49,274 | -139,427 | 19,803 | -241,896 |
Gain (Loss) on Sale of Investments | 214.05 | -1,396 | 12,243 | -2,858 | 51,477 | 1,987 |
Gain (Loss) on Sale of Assets | -18.81 | 171.02 | -18.72 | -11.28 | -3.02 | -0.29 |
Asset Writedown | 593.37 | - | -6,808 | -172.96 | - | - |
Pretax Income | 148,666 | 72,596 | -43,858 | -142,469 | 71,277 | -239,909 |
Income Tax Expense | -158,257 | -154,378 | -8,478 | -3,038 | 6,431 | 7,504 |
Earnings From Continuing Operations | 306,923 | 226,973 | -35,379 | -139,431 | 64,846 | -247,414 |
Net Income to Company | 306,923 | 226,973 | -35,379 | -139,431 | 64,846 | -247,414 |
Minority Interest in Earnings | 13,550 | 13,765 | 2,497 | - | - | - |
Net Income | 320,473 | 240,738 | -32,883 | -139,431 | 64,846 | -247,414 |
Net Income to Common | 320,473 | 240,738 | -32,883 | -139,431 | 64,846 | -247,414 |
Shares Outstanding (Basic) | 78 | 78 | 78 | 78 | 78 | 72 |
Shares Outstanding (Diluted) | 78 | 78 | 78 | 78 | 78 | 72 |
Shares Change (YoY) | - | - | - | - | 9.12% | 10.41% |
EPS (Basic) | 4092.19 | 3074.04 | -419.89 | -1780.43 | 828.03 | -3447.52 |
EPS (Diluted) | 4092.19 | 3074.04 | -419.89 | -1780.43 | 828.03 | -3447.52 |
Free Cash Flow | 143,051 | 93,505 | -96,586 | -164,831 | -97,188 | -221,749 |
Free Cash Flow Per Share | 1826.65 | 1193.98 | -1233.34 | -2104.77 | -1241.01 | -3089.90 |
Gross Margin | 94.99% | 92.13% | 90.40% | 84.66% | 94.66% | 92.41% |
Operating Margin | 29.36% | 17.59% | -10.57% | -53.24% | 22.68% | -921.18% |
Profit Margin | 47.45% | 43.96% | -9.27% | -56.64% | 15.49% | -951.63% |
Free Cash Flow Margin | 21.18% | 17.08% | -27.22% | -66.96% | -23.21% | -852.91% |
EBITDA | 215,767 | 113,767 | -22,205 | -118,094 | 106,600 | -228,640 |
EBITDA Margin | 31.95% | 20.78% | -6.26% | -47.97% | 25.46% | - |
D&A For EBITDA | 17,452 | 17,428 | 15,317 | 12,984 | 11,642 | 10,859 |
EBIT | 198,315 | 96,340 | -37,522 | -131,078 | 94,958 | -239,499 |
EBIT Margin | 29.36% | 17.59% | -10.57% | -53.24% | 22.68% | - |
Effective Tax Rate | - | - | - | - | 9.02% | - |
Advertising Expenses | - | 44,487 | 38,926 | 48,476 | 38,775 | 24,706 |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.